SCHEMBL135635

SCHEMBL135635

CCCCCCCCCCCCCCCCCCN(Cc1ccccn1)Cc1ccccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
MAPT P10636 1/20 0.68
LIN28A Q9H9Z2 1/20 0.68
TERT O14746 1/20 0.48
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
CXCR4 P61073 2/20 0.45
KCNH2 Q12809 3/20 0.45
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
KDM4E B2RXH2 3/20 0.43
POLB P06746 1/20 0.43
TSHR P16473 1/20 0.43
KCNA5 P22460 3/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29898520 1.00 TDP1 (0.68) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL1051354 1.00 TDP1 (0.68) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL29402044 1.00 TDP1 (0.68) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL15177847 1.00 TDP1 (0.68) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL230599 0.98 TDP1 (0.70) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL825181 0.97 TDP1 (0.69) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL1332466 0.97 TDP1 (0.69) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL825403 0.97 TDP1 (0.69) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL27681560 0.97 TDP1 (0.62) TDP1SMN1; SMN2MAPTLIN28ATERT
SCHEMBL3936898 0.94 TDP1 (0.59) TDP1SMN1; SMN2MAPTLIN28ATERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431673-A Preparation method of extremely cold special oil product viscosity index improver 新乡市瑞丰新材料股份有限公司 2025-02-14 CN claimed
CN-116023577-B Amphiphilic copper-containing polymer nanoparticle and preparation and application thereof 浙江大学 2023-10-03 CN claimed
CN-114775264-B Method for preparing nitrogen halamine type antibacterial cotton fabric by ATRP method 安徽大学 2023-06-23 CN claimed
CN-116023577-A Amphiphilic copper-containing polymer nanoparticle and preparation and application thereof 浙江大学 2023-04-28 CN claimed
CN-114159629-B High-speed preparation method of blood vessel covered stent for emergency treatment of sudden coronary perforation in operation 哈尔滨工业大学 2023-03-24 CN claimed
CN-113195644-B Coating against a substrate by in situ polymerization 汉高股份有限及两合公司 2023-01-24 CN claimed
CN-114775264-A Method for preparing N-halamine type antibacterial cotton fabric by ATRP (atom transfer radical polymerization) method 安徽大学 2022-07-22 CN claimed
CN-114159629-A High-speed preparation method of blood vessel covered stent for emergency treatment of sudden coronary perforation in operation 哈尔滨工业大学 2022-03-11 CN claimed
US-20200163899-A1 FUNCTIONALIZED PRUSSIAN BLUE NANOPARTICLES, COMBINATION PRUSSIAN BLUE NANOPARTICLE-BASED NANO-IMMUNOTHERAPY AND APPLICATIONS THEREOF CHILDREN'S NATIONAL MEDICAL CENTER (US) 2020-05-28 US claimed
EP-3426300-A1 FUNCTIONALIZED PRUSSIAN BLUE NANOPARTICES, COMBINATION PRUSSIAN BLUE NANOPARTICLE-BASED NANO-IMMUNOTHERAPHY AND APPLICATIONS THEREOF CHILDREN'S NATIONAL MEDICAL CENTER (US) 2019-01-16 EP claimed
EP-3397276-A1 ANTIBODIES AND CONJUGATES THEREOF Kodiak Sciences Inc. (US) 2018-11-07 EP claimed
CN-108712911-A Antibody and its conjugate 科达制药股份有限公司 2018-10-26 CN claimed
WO-2017156148-A1 FUNCTIONALIZED PRUSSIAN BLUE NANOPARTICES, COMBINATION PRUSSIAN BLUE NANOPARTICLE-BASED NANO-IMMUNOTHERAPHY AND APPLICATIONS THEREOF FERNANDES ROHAN (US) 2017-09-14 WO claimed
WO-2017117464-A1 ANTIBODIES AND CONJUGATES THEREOF KODIAK SCIENCES INC. (US) 2017-07-06 WO claimed
EP-4724108-A2 COMPOSITIONS OF CONJUGATED AND UNCONJUGATED PROTEINS Kodiak Sciences Inc. (US) 2026-04-15 EP disclosed
EP-4649959-A2 METHODS OF TREATING AN EYE DISORDER Kodiak Sciences Inc. (US) 2025-11-19 EP disclosed
US-12466879-B2 Complement factor D antagonist antibodies and conjugates thereof KODIAK SCIENCES INC. (US) 2025-11-11 US disclosed
WO-2007025086-A2 ATOM TRANSFER RADICAL POLYMERIZATION IN MICROEMULSION AND TRUE EMULSION POLYMERIZATION CARNEGIE MELLON UNIVERSITY (US) 2007-03-01 WO disclosed
EP-1725590-A1 ATOM TRANSFER RADICAL POLYMERIZATION PROCESS CARNEGIE-MELLON UNIVERSITY (US) 2006-11-29 EP disclosed
WO-2005087819-A1 ATOM TRANSFER RADICAL POLYMERIZATION PROCESS CARNEGIE MELLON UNIVERSITY (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466879-B2 Complement factor D antagonist antibodies and conjugates thereof CFD, CFH, CFB TDP1 4046/4885SMN1; SMN2 3074/4885MAPT 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.